Actionable news
0
All posts from Actionable news
Actionable news in LOXO: LOXO ONCOLOGY INC,

Loxo Oncology Announces Transition Of Chief Medical Officer

The following excerpt is from the company's SEC filing.

STAMFORD, Conn., November 5, 2015

Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that Jennifer Low, M.D., Ph.D., chief medical officer and executive vice president, R&D, has decided to transition from her current role with Loxo Oncology. Over the next several months, Dr. Low will remain at Loxo Oncology as acting chief medical officer, as an employee through the end of 2015 and in an advisory role thereafter.

I would like to thank Jennifer, a longtime friend, for her contributions during a formative period at Loxo Oncology, said Josh Bilenker, M.D., chief executive officer of Loxo Oncology. With LOXO-101 enrolling in Phase 2, and our pipeline well-positioned for the clinic, the time was right for Jennifer to consider her next activities, both personally and professionally. Her transition has no effect on our current clinical plans or timelines, and I am confident we will continue to execute well against the full potential of our pipeline.

I am grateful for my time at Loxo Oncology and the opportunity to be part of its innovative approach to drug development. I have enjoyed...


More